The progress of postapproval clinical studies on Sabin IPV
As one of the powerful vaccines for completely eradicating all types of poliovirus in the polio endgame period, the novel IPV, which is prepared from attenuated polio Sabin strains (sIPV) and is expected to reduce the overall biosafety risk, was licensed in Japan (sIPV-containing diphtheria-tetanus-...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1940653 |
| _version_ | 1797673945381470208 |
|---|---|
| author | Li Shi Mingbo Sun |
| author_facet | Li Shi Mingbo Sun |
| author_sort | Li Shi |
| collection | DOAJ |
| description | As one of the powerful vaccines for completely eradicating all types of poliovirus in the polio endgame period, the novel IPV, which is prepared from attenuated polio Sabin strains (sIPV) and is expected to reduce the overall biosafety risk, was licensed in Japan (sIPV-containing diphtheria-tetanus-acellular pertussis combination vaccines, DTP-sIPV) and China (sIPV) in November 2012 and January 2015, respectively. Limited by the development progress and the manufactured sIPV ability, it has to date only been used in Chinese Expanded Programme on Immunization (EPI) by sequential scheduling with bOPV and in Japan with DTP-sIPV vaccination. We herein summarize postapproval clinical studies of sIPV in both full-dose schedules and sequential schedules, focusing on China, to evaluate sIPV safety and immunogenicity in large populations to provide important data for its broad application in developing countries worldwide. |
| first_indexed | 2024-03-11T21:51:48Z |
| format | Article |
| id | doaj.art-c2256451dddd41748b20165d84a33519 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:51:48Z |
| publishDate | 2022-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-c2256451dddd41748b20165d84a335192023-09-26T08:59:30ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-01-011811410.1080/21645515.2021.19406531940653The progress of postapproval clinical studies on Sabin IPVLi Shi0Mingbo Sun1Chinese Academy of Medical Sciences & Peking Union Medical CollegeChinese Academy of Medical Sciences & Peking Union Medical CollegeAs one of the powerful vaccines for completely eradicating all types of poliovirus in the polio endgame period, the novel IPV, which is prepared from attenuated polio Sabin strains (sIPV) and is expected to reduce the overall biosafety risk, was licensed in Japan (sIPV-containing diphtheria-tetanus-acellular pertussis combination vaccines, DTP-sIPV) and China (sIPV) in November 2012 and January 2015, respectively. Limited by the development progress and the manufactured sIPV ability, it has to date only been used in Chinese Expanded Programme on Immunization (EPI) by sequential scheduling with bOPV and in Japan with DTP-sIPV vaccination. We herein summarize postapproval clinical studies of sIPV in both full-dose schedules and sequential schedules, focusing on China, to evaluate sIPV safety and immunogenicity in large populations to provide important data for its broad application in developing countries worldwide.http://dx.doi.org/10.1080/21645515.2021.1940653sipvpostapproval clinical studiesfull-dose and sequential vaccinationsafetyimmunogenicity |
| spellingShingle | Li Shi Mingbo Sun The progress of postapproval clinical studies on Sabin IPV Human Vaccines & Immunotherapeutics sipv postapproval clinical studies full-dose and sequential vaccination safety immunogenicity |
| title | The progress of postapproval clinical studies on Sabin IPV |
| title_full | The progress of postapproval clinical studies on Sabin IPV |
| title_fullStr | The progress of postapproval clinical studies on Sabin IPV |
| title_full_unstemmed | The progress of postapproval clinical studies on Sabin IPV |
| title_short | The progress of postapproval clinical studies on Sabin IPV |
| title_sort | progress of postapproval clinical studies on sabin ipv |
| topic | sipv postapproval clinical studies full-dose and sequential vaccination safety immunogenicity |
| url | http://dx.doi.org/10.1080/21645515.2021.1940653 |
| work_keys_str_mv | AT lishi theprogressofpostapprovalclinicalstudiesonsabinipv AT mingbosun theprogressofpostapprovalclinicalstudiesonsabinipv AT lishi progressofpostapprovalclinicalstudiesonsabinipv AT mingbosun progressofpostapprovalclinicalstudiesonsabinipv |